Progress in small-cell lung cancer: the lowest common denominator.


Progress in the therapy of small-cell lung cancer (SCLC), commonly viewed at initial presentation as one of the most highly chemotherapy-sensitive solid tumors, has been painfully slow. In fact, it could be argued that little to no therapeutic advances have been made for extensive stage patients in more than 20 years. In a disease uniquely positioned from… (More)
DOI: 10.1200/JCO.2008.17.2692


1 Figure or Table

Slides referencing similar topics